Patents Represented by Attorney Lawrence B. Bugaisky

Find this attorney in the Justia Lawyer Directory

  • Peptides and related molecules that modulate nerve growth factor activity
    Patent number: 8124724
    Abstract: The present invention relates to certain biologically active peptides and polypeptides which can be used as therapeutics or prophylactics against diseases or disorders linked to NGF as the causative agent. In one aspect of the present invention, pharmacologically active polypeptides comprising peptides linked to one or more Fc domains are provided.
    Type: Grant
    Filed: January 24, 2008
    Date of Patent: February 28, 2012
    Assignee: Amgen Inc.
    Inventors: Thomas C. Boone, Kenneth C. Wild, Karen C. Sitney, Hosung Min, Bruce Kimmel
  • Isolated nucleic acid molecule comprising the amino acid sequence of SEQ ID NO:1
    Patent number: 8067562
    Abstract: The present invention provides novel activin IIB5 receptor polypeptides capable of binding and inhibiting the activities of activin A, myostatin, or GDF-11. The present invention also provides polynucleotides, vectors and host cells capable of producing the receptor polypeptides. Compositions and methods for treating muscle-wasting, metabolic and other disorders are also provided.
    Type: Grant
    Filed: October 31, 2006
    Date of Patent: November 29, 2011
    Assignee: Amgen Inc.
    Inventors: HQ Han, Keith Soo-Nyung Kwak, Xiaolan Zhou
  • Variant activin receptor polypeptides
    Patent number: 7947646
    Abstract: The present invention provides variant activin IIB soluble receptor polypeptides and proteins capable of binding and inhibiting the activities of activin A, myostatin, or GDF-11. The present invention also provides polynucleotides, vectors and host cells capable of producing the variant polypeptides and proteins. Compositions and methods for treating muscle-wasting and other diseases and disorders are also provided.
    Type: Grant
    Filed: March 5, 2008
    Date of Patent: May 24, 2011
    Assignee: Amgen Inc.
    Inventors: Jeonghoon Sun, Lei-Ting Tony Tam, Hui-Quan Han, Keith Soo-Nyung Kwak, Xiaolan Zhou
  • Polynucleotides encoding truncated glial cell line-derived neurotrophic factor
    Patent number: 7611865
    Abstract: Disclosed are novel proteins, referred to as truncated glial cell line-derived neurotrophic factor (truncated GDNF) proteins, that promote dopamine uptake by dopaminergic cells and promote the survival of nerve cells. Also disclosed are processes for obtaining the truncated GDNF proteins by recombinant genetic engineering techniques.
    Type: Grant
    Filed: May 26, 2004
    Date of Patent: November 3, 2009
    Assignee: Amgen Inc.
    Inventor: Shaw-Fen Sylvia Hu
  • Methods of using truncated glial cell line-derived neurotrophic factor
    Patent number: 7390781
    Abstract: Disclosed are novel proteins, referred to as truncated glial cell line-derived neurotrophic factor (truncated GDNF) proteins, that promote dopamine uptake by dopaminergic cells and promote the survival of nerve cells. Also disclosed are processes for obtaining the truncated GDNF proteins by recombinant genetic engineering techniques.
    Type: Grant
    Filed: January 7, 2004
    Date of Patent: June 24, 2008
    Assignee: Amgen Inc.
    Inventor: Shaw-Fen Sylvia Hu
  • Peptides and related molecules that modulate nerve growth factor activity
    Patent number: 7371559
    Abstract: The present invention relates to certain biologically active peptides and polypeptides which can be used as therapeutics or prophylactics against diseases or disorders linked to NGF as the causative agent. In one aspect of the present invention, pharmacologically active polypeptides comprising peptides linked to one or more Fc domains are provided.
    Type: Grant
    Filed: May 11, 2005
    Date of Patent: May 13, 2008
    Assignee: Amgen Inc.
    Inventors: Thomas C. Boone, Kenneth C. Wild, Karen C. Sitney, Hosung Min, Bruce Kimmel